SABS

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SABS) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (C-). The rating has held at C for 11 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.1
EV / EBITDA -2.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -21.5%
Price Return 12M -13.2%
Catalyst Signal 0.00
Market Cap $266.7M
TTM Revenue N/A
Price / Sales N/A
ROE -42.8%

Historical Factor Score Progression

Held C for 11 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C- (2.1) C (2.4) C- (2.0) C+ (2.6) C (2.3)
2026-11-07 C+ (2.5) C (2.2) C- (2.0) C- (2.1) C+ (2.7) C (2.3)
2026-10-31 C+ (2.5) C- (2.1) C+ (2.6) C (2.4) C+ (2.7) C (2.5)
2026-10-24 C+ (2.5) C- (2.1) C+ (2.6) C (2.4) C+ (2.6) C (2.4)
2026-10-17 C+ (2.5) C- (2.1) C+ (2.6) C (2.4) C+ (2.6) C (2.4)
Page 1 of 4